← Back to Search

Radiation

Radiation Therapy for Breast Cancer (DCIS Trial)

N/A
Waitlist Available
Research Sponsored by Trans Tasman Radiation Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women ≥ 18 years.
Histologically proven DCIS of the breast without an invasive component.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at baseline, last week of rt, 3, 6, and 12 months post rt and then yearly until year 10.
Awards & highlights

DCIS Trial Summary

This trial is testing whether adding a tumour bed boost after breast conserving surgery (BCS) in women with non-low risk ductal carcinoma in situ (DCIS) reduces the risk of local recurrence. There are two fractionation arms in this trial: a shorter fractionation arm and a standard fractionation arm. The overall objectives of the trial are to improve the outcome of women with non-low risk DCIS treated with BCS and to individualize treatment selection for women with DCIS to achieve long term disease control with minimal toxicity.

Who is the study for?
This trial is for women over 18 with non-low risk DCIS of the breast, treated by breast conserving surgery. They must be clinically node-negative, able to start radiation within 12 weeks post-surgery, and have a life expectancy over 5 years. Exclusions include pregnant or lactating women, those with lymph node tumor cells, bilateral DCIS, previous contralateral breast cancer or serious diseases like scleroderma.Check my eligibility
What is being tested?
The study tests if adding a boost after whole breast radiation (WBRT) reduces recurrence in high-risk DCIS patients and compares shorter vs standard WBRT schedules. It also aims to find molecular signatures predicting invasive recurrence to personalize treatment.See study design
What are the potential side effects?
While not explicitly listed here, potential side effects generally associated with radiation therapy may include skin irritation at the treatment site, fatigue, mild swelling in the treated area and changes in breast texture.

DCIS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 18 or older.
Select...
My breast cancer is non-invasive and confirmed by tissue analysis.
Select...
I am at high risk of breast cancer returning due to my age and specific tumor characteristics.
Select...
My cancer has not spread to my lymph nodes.
Select...
My radiation therapy will start no later than 12 weeks after my last surgery.
Select...
I have had mammograms of both breasts in the last 6 months.
Select...
My breast cancer surgery removed all cancer with clear edges of at least 1mm.
Select...
I can take care of myself and perform daily activities.
Select...
My surgeon and radiation oncologist agree I can have breast-saving surgery and radiation.

DCIS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at baseline, last week of rt, 6, 12, 24, 60 & 120 months post rt.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at baseline, last week of rt, 6, 12, 24, 60 & 120 months post rt. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to local recurrence, measured from the date of randomization to the date of first evidence of local recurrence.
Secondary outcome measures
Cosmetic Outcome
Overall survival
Quality of Life change
+2 more

DCIS Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Arm 4 (Shorter WB fractionation + Boost)Experimental Treatment1 Intervention
Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
Group II: Arm 2 (Shorter WB Fractionation)Experimental Treatment1 Intervention
Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
Group III: Arm 1 (Standard WB Fractionation)Active Control1 Intervention
Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
Group IV: Arm 3 (Standard WB fractionation+Boost)Active Control1 Intervention
Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)

Find a Location

Who is running the clinical trial?

Scottish Cancer Trials Breast GroupUNKNOWN
Trans Tasman Radiation Oncology GroupLead Sponsor
48 Previous Clinical Trials
15,021 Total Patients Enrolled
Borstkanker Onderzoek GroepNETWORK
20 Previous Clinical Trials
9,560 Total Patients Enrolled

Media Library

Shorter WB fractionation (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT00470236 — N/A
Breast Carcinoma Research Study Groups: Arm 1 (Standard WB Fractionation), Arm 4 (Shorter WB fractionation + Boost), Arm 3 (Standard WB fractionation+Boost), Arm 2 (Shorter WB Fractionation)
Breast Carcinoma Clinical Trial 2023: Shorter WB fractionation Highlights & Side Effects. Trial Name: NCT00470236 — N/A
Shorter WB fractionation (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00470236 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Shorter WB fractionation a danger to patients?

"There is some clinical evidence supporting the efficacy of Shorter WB fractionation, as well as data from multiple rounds of testing which supports its safety. This gives it a score of 3 on our scale."

Answered by AI

Are there many locations in the United States conducting this research study?

"Currently, this research is being conducted in 20 different locations. They are located in Kelowna, Victoria and Hearst as well as 20 other cities. If you choose to participate, it would be beneficial to select a site near you to limit travel expenses."

Answered by AI

Are investigators still enrolling individuals for this research?

"Unfortunately, this particular study is no longer looking for patients. Although it was last updated on December 3rd, 2019, the trial originally posted on June 1st, 2007. There are 2615 other trials that are still open and recruiting right now."

Answered by AI
Recent research and studies
~16 spots leftby Jun 2024